We use cookies to enhance your browsing experience, analyze website traffic, and maintain essential site functionality. By clicking "Accept All", you consent to our use of cookies. For more details, please review our Privacy Policy.

Morphic Stock (NASDAQ:MORF)



Previous Close

$56.97

52W Range

$19.34 - $57.00

50D Avg

$44.96

200D Avg

$33.56

Market Cap

$2.86B

Avg Vol (3M)

$2.45M

Beta

1.49

Div Yield

-

MORF Company Profile


Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

128

IPO Date

Jun 27, 2019

Website

MORF Performance


Total Return %
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
MORF
S&P 500
0.00%
0.00%
0.04%
115.46%
65.00%
96.99%
3.39%
-14.76%
199.16%
216.61%
0.14%
-3.24%
-7.18%
-11.91%
-9.95%
-9.96%
6.31%
18.28%
86.94%
150.85%

Latest Earnings Call Transcripts


Q4 20Mar 01, 21 | 2:28 PM

Peer Comparison


TickerCompany
PTGXProtagonist Therapeutics, Inc.
ETNB89bio, Inc.
VKTXViking Therapeutics, Inc.
MDGLMadrigal Pharmaceuticals, Inc.
AKROAkero Therapeutics, Inc.
RVMDRevolution Medicines, Inc. Warrant
STOKStoke Therapeutics, Inc.
RNAAvidity Biosciences, Inc.
PLRXPliant Therapeutics, Inc.
IMCRImmunocore Holdings plc

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools